FR2730491B1 - Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent - Google Patents

Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent

Info

Publication number
FR2730491B1
FR2730491B1 FR9501489A FR9501489A FR2730491B1 FR 2730491 B1 FR2730491 B1 FR 2730491B1 FR 9501489 A FR9501489 A FR 9501489A FR 9501489 A FR9501489 A FR 9501489A FR 2730491 B1 FR2730491 B1 FR 2730491B1
Authority
FR
France
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
transferase inhibitors
farnesyl transferase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9501489A
Other languages
English (en)
Other versions
FR2730491A1 (fr
Inventor
Francois Clerc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9501489A priority Critical patent/FR2730491B1/fr
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Priority to EP96903061A priority patent/EP0808328A1/fr
Priority to PCT/FR1996/000198 priority patent/WO1996024611A1/fr
Priority to KR1019970705443A priority patent/KR19980702048A/ko
Priority to US08/875,752 priority patent/US5856439A/en
Priority to CA002210955A priority patent/CA2210955A1/fr
Priority to CZ972498A priority patent/CZ249897A3/cs
Priority to SK1087-97A priority patent/SK108797A3/sk
Priority to PL96321675A priority patent/PL321675A1/xx
Priority to JP8524037A priority patent/JPH10513467A/ja
Priority to CN96191867A priority patent/CN1173874A/zh
Priority to AU47227/96A priority patent/AU4722796A/en
Priority to BR9607317A priority patent/BR9607317A/pt
Priority to TR97/00727T priority patent/TR199700727T1/xx
Priority to ZA961072A priority patent/ZA961072B/xx
Publication of FR2730491A1 publication Critical patent/FR2730491A1/fr
Publication of FR2730491B1 publication Critical patent/FR2730491B1/fr
Application granted granted Critical
Priority to NO973608A priority patent/NO973608D0/no
Priority to MXPA/A/1997/006015A priority patent/MXPA97006015A/xx
Priority to FI973278A priority patent/FI973278A/fi
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR9501489A 1995-02-09 1995-02-09 Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent Expired - Fee Related FR2730491B1 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
FR9501489A FR2730491B1 (fr) 1995-02-09 1995-02-09 Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
BR9607317A BR9607317A (pt) 1995-02-09 1996-02-07 Peptídios e composição farmacêutica
PCT/FR1996/000198 WO1996024611A1 (fr) 1995-02-09 1996-02-07 Inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
US08/875,752 US5856439A (en) 1995-02-09 1996-02-07 Farnesyl transferase inhibitors, preparation thereof, and pharmaceutical compositions containing same
CA002210955A CA2210955A1 (fr) 1995-02-09 1996-02-07 Inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
CZ972498A CZ249897A3 (en) 1995-02-09 1996-02-07 Novel inhibitors of farnesyl transferase, process of their preparation and pharmaceutical compositions containing such inhibitors
SK1087-97A SK108797A3 (en) 1995-02-09 1996-02-07 Novel farnesyl transferase inhibitors, preparation thereof, and pharmaceutical compositions containing same
PL96321675A PL321675A1 (en) 1995-02-09 1996-02-07 Novel inhibitors of farnesil transferase, their production and pharmaceutic compositions containing them
TR97/00727T TR199700727T1 (xx) 1995-02-09 1996-02-07 Farnesil transferaz�n�n yeni inhibit�rleri.
CN96191867A CN1173874A (zh) 1995-02-09 1996-02-07 新的法呢基转移酶抑制剂,其制法及其药物组合物
EP96903061A EP0808328A1 (fr) 1995-02-09 1996-02-07 Inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
KR1019970705443A KR19980702048A (ko) 1995-02-09 1996-02-07 신규한 파르네실 트랜스퍼라아제 억제제, 이의 제조방법 및 이를 함유하는 약학 조성물
JP8524037A JPH10513467A (ja) 1995-02-09 1996-02-07 ファルネシル転移酵素阻害剤、これらの調製、及びこれらを含む製薬学的組成物
AU47227/96A AU4722796A (en) 1995-02-09 1996-02-07 Novel farnesyl transferase inhibitors, preparation thereof, and pharmaceutical compositions containing same
ZA961072A ZA961072B (en) 1995-02-09 1996-02-09 New farnesyl transferase inhibitors their preparation and the pharmaceutical compositions which contain them
NO973608A NO973608D0 (no) 1995-02-09 1997-08-05 Nye farnesyl-transferaseinhibitorer, deres fremstilling samt farmasöytiske preparater inneholdende forbindelsene
MXPA/A/1997/006015A MXPA97006015A (en) 1995-02-09 1997-08-06 Novedous inhibitors of farnesil transferase, supreparation and pharmaceutical compositions chelos contie
FI973278A FI973278A (fi) 1995-02-09 1997-08-08 Uudet farnesyylitransferaasin inhibiittorit, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9501489A FR2730491B1 (fr) 1995-02-09 1995-02-09 Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
FR2730491A1 FR2730491A1 (fr) 1996-08-14
FR2730491B1 true FR2730491B1 (fr) 1997-03-14

Family

ID=9475979

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9501489A Expired - Fee Related FR2730491B1 (fr) 1995-02-09 1995-02-09 Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent

Country Status (17)

Country Link
US (1) US5856439A (fr)
EP (1) EP0808328A1 (fr)
JP (1) JPH10513467A (fr)
KR (1) KR19980702048A (fr)
CN (1) CN1173874A (fr)
AU (1) AU4722796A (fr)
BR (1) BR9607317A (fr)
CA (1) CA2210955A1 (fr)
CZ (1) CZ249897A3 (fr)
FI (1) FI973278A (fr)
FR (1) FR2730491B1 (fr)
NO (1) NO973608D0 (fr)
PL (1) PL321675A1 (fr)
SK (1) SK108797A3 (fr)
TR (1) TR199700727T1 (fr)
WO (1) WO1996024611A1 (fr)
ZA (1) ZA961072B (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2730491B1 (fr) * 1995-02-09 1997-03-14 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
EP1888050B1 (fr) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. Acide cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl) cyclohexanepropanoique pour le traitement du cancer
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2664113C (fr) 2006-09-22 2013-05-28 Merck & Co., Inc. Utilisation de la platencine et de la platensimycine en tant qu'inhibiteurs de la synthese des acides gras pour traiter l'obesite, lediabete et le cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
RS51780B (en) 2007-01-10 2011-12-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. INDASOLS SUBSTITUTED BY AMIDE AS INHIBITORS OF POLY (ADP-Ribose) POLYMERASES (PARP)
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
AU2008254425A1 (en) 2007-05-21 2008-11-27 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
EP3103791B1 (fr) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. Dérivés de 4-carboxybenzylamino utilisés comme inhibiteurs de l'histone désacétylase
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
WO2010144909A1 (fr) 2009-06-12 2010-12-16 Novartis Ag Composés hétérocycliques fondus et leurs utilisations
KR101485645B1 (ko) 2009-10-14 2015-01-22 머크 샤프 앤드 돔 코포레이션 ｐ53 활성을 증가시키는 치환된 피페리딘 및 그의 용도
EP2937345B1 (fr) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase raf de type ii
WO2011115725A2 (fr) 2010-03-16 2011-09-22 Dana-Farber Cancer Institute, Inc. Composés d'indazole et leurs utilisations
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
EP2598874B1 (fr) 2010-07-28 2018-10-24 Janssen Diagnostics, LLC Procédés de détermination de réponse de la leucémie myéloïde aiguë à traitement par inhibiteurs de la farnésyltransférase
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
WO2012024170A2 (fr) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (fr) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
EP2615916B1 (fr) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
EP2654748B1 (fr) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
WO2012143879A1 (fr) 2011-04-21 2012-10-26 Piramal Healthcare Limited Forme cristalline d'un sel d'un dérivé de morpholinosulfonylindole et son procédé de préparation
EP2770987B1 (fr) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
EP2822935B1 (fr) 2011-11-17 2019-05-15 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase c-jun-terminale (jnk)
EP3919620A1 (fr) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
WO2014052563A2 (fr) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Nouveaux composés inhibiteurs de erk
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2014063054A1 (fr) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase moelle osseuse sur chromosome x (bmx) et leurs utilisations
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
JP6387013B2 (ja) 2012-12-20 2018-09-12 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｈｄｍ２阻害薬としての置換されたイミダゾピリジン類
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
WO2015034925A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides circulaires
AU2014337122B2 (en) 2013-10-18 2019-01-03 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (fr) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase et leurs utilisations
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
JP6861166B2 (ja) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
EP3307728A4 (fr) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases
ES2741782T3 (es) 2015-08-17 2020-02-12 Kura Oncology Inc Métodos para tratar pacientes con cáncer a partir de inhibidores de la farnesiltransferasa
WO2017044858A2 (fr) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dépendantes
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
EP3525785A4 (fr) 2016-10-12 2020-03-25 Merck Sharp & Dohme Corp. Inhibiteurs de kdm5
SI3534885T1 (sl) 2016-11-03 2021-08-31 Kura Oncology, Inc. Zaviralci farnezil-transferaze za uporabo pri zdravljenju raka
MX2019012233A (es) 2017-04-13 2020-01-14 Aduro Biotech Holdings Europe Bv Anticuerpos anti-sirpa.
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019113269A1 (fr) 2017-12-08 2019-06-13 Kura Oncology, Inc. Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
WO2019148412A1 (fr) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anticorps bispécifiques anti-pd-1/lag3
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833668A4 (fr) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2024180169A1 (fr) 2023-03-02 2024-09-06 Carcimun Biotech Gmbh Moyens et procédés de diagnostic du cancer et/ou d'une maladie inflammatoire aiguë

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141851A (en) * 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
CA2044333A1 (fr) * 1990-06-12 1991-12-13 Jackson B. Gibbs Agents chimiotherapeutiques
CA2072033A1 (fr) * 1991-06-28 1992-12-29 Jackson B. Gibbs Inhibiteur de la farnesyl-proteine-transferase ne se rapportant pas a un substrat
CA2118985A1 (fr) * 1993-04-02 1994-10-03 Dinesh V. Patel Inhibiteurs heterocycliques de la farnesyl proteine transferase
US5843941A (en) * 1993-05-14 1998-12-01 Genentech, Inc. Ras farnesyl transferase inhibitors
US5439918A (en) * 1994-03-14 1995-08-08 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
FR2730491B1 (fr) * 1995-02-09 1997-03-14 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2730492B1 (fr) * 1995-02-09 1997-03-14 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
US5856439A (en) 1999-01-05
AU4722796A (en) 1996-08-27
FI973278A0 (fi) 1997-08-08
FI973278A (fi) 1997-08-08
CZ249897A3 (en) 1997-11-12
ZA961072B (en) 1996-08-20
KR19980702048A (ko) 1998-07-15
MX9706015A (es) 1997-11-29
BR9607317A (pt) 1997-12-30
SK108797A3 (en) 1997-12-10
TR199700727T1 (xx) 1998-02-21
CA2210955A1 (fr) 1996-08-15
CN1173874A (zh) 1998-02-18
WO1996024611A1 (fr) 1996-08-15
NO973608L (no) 1997-08-05
JPH10513467A (ja) 1998-12-22
PL321675A1 (en) 1997-12-22
EP0808328A1 (fr) 1997-11-26
FR2730491A1 (fr) 1996-08-14
NO973608D0 (no) 1997-08-05

Similar Documents

Publication Publication Date Title
FR2736641B1 (fr) Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2736638B1 (fr) Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2730491B1 (fr) Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2730492B1 (fr) Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2742751B1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2727411B1 (fr) Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent
DZ2009A1 (fr) Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2676446B1 (fr) Nouveaux derives du thiopyranopyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2683531B1 (fr) Nouveaux derives du lupane, leur preparation et les compositions pharmaceutiques qui les contiennent.
ZA96258B (en) New farnesyl tranferase inhibitors their preparation and the pharmaceutical compositions which contain them
FR2642069B1 (fr) Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2732968B1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2779724B1 (fr) Derives du pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757166B1 (fr) Derives du pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2687151B1 (fr) Nouveaux derives de la baccatine iii et de la desacetyl-10 baccatine iii, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2745814B1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2732342B1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2712288B1 (fr) Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2712289B1 (fr) Nouveaux dérivés de taxicine, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2721021B1 (fr) Nouveaux inhibiteurs de farnésyl transférase, leur préparation et les compositions pharmaceutique qui les contiennent.
FR2705094B1 (fr) Nouveaux dérivés du lupane, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2705097B1 (fr) Nouveaux dérivés du lupane, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2721023B1 (fr) Nouveaux Taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2757855B1 (fr) Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2733498B1 (fr) Nouveaux composes cyclohexaniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Legal Events

Date Code Title Description
ST Notification of lapse